Healthcare & Medical Devices Global On demand · 24-48h

Global Genotyping Kits Market Strategic Research Report

Global Genotyping Kits Market Strategic Research Report
$3,500 USD
Market Research Reports
Strategic Research Report
Global Genotyping Kits Market
$1.35B2025
12.2%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: PCR-Based Kits, Next-Generation Sequencing (NGS) Kits, Microarray-Based Kits

By Application: Medical Diagnostics, Biological Research, Forensic Science, Drug Development, Others

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: Roche, Thermo Fisher Scientific, Merck, Illumina, Bio-Rad, Promega, Fujirebio, Seegene, Bionano Genomics, Creative Enzymes, Yaneng Biological Technology, Triplex International Biosciences, Hangzhou KBM Life Sciences, ROSE Genomics, Daan Gene, Hybribio Biotech, Wuhan Easy Diagnosis Biomedicine, Microread Genetics, Uni-medica, RayBiotech, Quantabio, Paragon Genomics, Grifols, BGI

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 150 pages
Market size 2025
$1.35B
Billion USD
Forecast CAGR
12.2%
2025-2032
Forecast 2032
$3B
Projected
Regions
5
Asia Pacific · Latin America · MEA · Europe · North America

Overview

Scope of the Report

The global Genotyping Kits market size is predicted to grow from US$ 1,348 million in 2025 to US$ 2,981 million in 2032; it is expected to grow at a CAGR of 12.2% from 2026 to 2032.

In 2024, the global production of genotyping kits is reach 850,000 units, with an average price of US$1,500 per unit.

Genotyping kits are laboratory tools used to identify genetic variations within DNA sequences. They are designed to detect specific genetic markers, such as single nucleotide polymorphisms (SNPs), insertions/deletions (indels), or larger structural variations, enabling researchers to study genetic traits, mutations, and variations across different samples.

The genotyping kit market is experiencing significant growth and technological change, driven by multiple factors. This growth is primarily driven by the rapid development of precision medicine, the increasing demand for early cancer screening and genetic disease diagnosis, and the continued decline in the cost of genetic sequencing.

North America and Europe remain the world's largest markets, but the Asia-Pacific region, particularly China and India, is becoming the fastest-growing region thanks to its large patient base, government policy support, and domestic technological breakthroughs. Technological advancement is a key driver of industry development. Next-generation sequencing (NGS) currently dominates due to its high throughput and high accuracy. Microarray technology also holds a significant share in clinical screening due to its cost advantages. Future technological development will move towards higher throughput, greater automation, and greater intelligence. The commercial application of cutting-edge technologies such as single-cell typing and nanopore real-time sequencing is accelerating.

On the supply chain side, import customs clearance for genotyping kits involves a series of specialized procedures, including qualification filing, providing documents such as MSDS (Material Safety Data Sheets), Chinese labeling, and compliance with customs regulations for the accurate declaration of product name, quantity, and value. Its manufacturing relies heavily on high-quality raw materials, such as fluorescent probes and enzymes. Currently, the domestic content rate for these raw materials remains below 30%, posing certain supply chain risks. The stability of the global supply chain is susceptible to geopolitical fluctuations and unexpected events, and prices of key raw materials are expected to rise in 2024. Therefore, localized supply chain deployment and stability assurance are gaining increasing importance. The market competition landscape is characterized by a "one superpower, many strong players." The international market is dominated by giants such as Illumina and Thermo Fisher Scientific, while Chinese companies such as BGI, Berry Genomics, and Daan Genomics are rapidly rising through localization strategies and technological innovation. Leading companies are building barriers through "vertical integration + ecological alliances." For example, BGI has connected the multi-omics data platform of 142 tertiary hospitals nationwide, while Berry Genomics has partnered with insurance companies to integrate genetic testing into health insurance products. Meanwhile, many small and medium-sized companies are focusing on specific disease markers or regional services, establishing differentiated advantages in niche markets.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Genotyping Kits market?

What factors are driving Genotyping Kits market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Genotyping Kits market opportunities vary by end market size?

How does Genotyping Kits break out by Type, by Application?

This report presents a comprehensive overview of the global Genotyping Kits market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • PCR-Based Kits
  • Next-Generation Sequencing (NGS) Kits
  • Microarray-Based Kits

Segment by Application

  • Medical Diagnostics
  • Biological Research
  • Forensic Science
  • Drug Development
  • Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Genotyping Kits market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Medical Diagnostics, Biological Research, Forensic Science evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Genotyping Kits Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 12.2%
Regional growth momentum
Market share by segment
Key metrics
Base value
$1.35B
2025
Forecast
$3B
2032
CAGR
12.2%
2025–2032
Regions
5
global
Key companies
RocheThermo Fisher ScientificMerckIlluminaBio-RadPromegaFujirebioSeegene
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
PCR-Based KitsNext-Generation Sequencing (NGS) KitsMicroarray-Based Kits
By Application
Medical DiagnosticsBiological ResearchForensic ScienceDrug DevelopmentOthers

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 PCR-Based Kits
  • 3.1.3 Next-Generation Sequencing (NGS) Kits
  • 3.1.4 Microarray-Based Kits
  • 3.1.5 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Medical Diagnostics
  • 4.1.3 Biological Research
  • 4.1.4 Forensic Science
  • 4.1.5 Drug Development
  • 4.1.6 Others
  • 4.1.7 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 Roche
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 Thermo Fisher Scientific
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 Merck
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 Illumina
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 Bio-Rad
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 Promega
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 Fujirebio
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 Seegene
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 Bionano Genomics
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 Creative Enzymes
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
  • 8.11 Yaneng Biological Technology
  • 8.11.1 Company Overview
  • 8.11.2 Key Products & Segments
  • 8.11.3 Financial Performance (2023–2025)
  • 8.11.4 Business Strategy
  • 8.11.5 SWOT Analysis
  • 8.11.6 Strategic Implications (2026–2032)
  • 8.12 Triplex International Biosciences
  • 8.12.1 Company Overview
  • 8.12.2 Key Products & Segments
  • 8.12.3 Financial Performance (2023–2025)
  • 8.12.4 Business Strategy
  • 8.12.5 SWOT Analysis
  • 8.12.6 Strategic Implications (2026–2032)
  • 8.13 Hangzhou KBM Life Sciences
  • 8.13.1 Company Overview
  • 8.13.2 Key Products & Segments
  • 8.13.3 Financial Performance (2023–2025)
  • 8.13.4 Business Strategy
  • 8.13.5 SWOT Analysis
  • 8.13.6 Strategic Implications (2026–2032)
  • 8.14 ROSE Genomics
  • 8.14.1 Company Overview
  • 8.14.2 Key Products & Segments
  • 8.14.3 Financial Performance (2023–2025)
  • 8.14.4 Business Strategy
  • 8.14.5 SWOT Analysis
  • 8.14.6 Strategic Implications (2026–2032)
  • 8.15 Daan Gene
  • 8.15.1 Company Overview
  • 8.15.2 Key Products & Segments
  • 8.15.3 Financial Performance (2023–2025)
  • 8.15.4 Business Strategy
  • 8.15.5 SWOT Analysis
  • 8.15.6 Strategic Implications (2026–2032)
  • 8.16 Hybribio Biotech
  • 8.16.1 Company Overview
  • 8.16.2 Key Products & Segments
  • 8.16.3 Financial Performance (2023–2025)
  • 8.16.4 Business Strategy
  • 8.16.5 SWOT Analysis
  • 8.16.6 Strategic Implications (2026–2032)
  • 8.17 Wuhan Easy Diagnosis Biomedicine
  • 8.17.1 Company Overview
  • 8.17.2 Key Products & Segments
  • 8.17.3 Financial Performance (2023–2025)
  • 8.17.4 Business Strategy
  • 8.17.5 SWOT Analysis
  • 8.17.6 Strategic Implications (2026–2032)
  • 8.18 Microread Genetics
  • 8.18.1 Company Overview
  • 8.18.2 Key Products & Segments
  • 8.18.3 Financial Performance (2023–2025)
  • 8.18.4 Business Strategy
  • 8.18.5 SWOT Analysis
  • 8.18.6 Strategic Implications (2026–2032)
  • 8.19 Uni-medica
  • 8.19.1 Company Overview
  • 8.19.2 Key Products & Segments
  • 8.19.3 Financial Performance (2023–2025)
  • 8.19.4 Business Strategy
  • 8.19.5 SWOT Analysis
  • 8.19.6 Strategic Implications (2026–2032)
  • 8.20 RayBiotech
  • 8.20.1 Company Overview
  • 8.20.2 Key Products & Segments
  • 8.20.3 Financial Performance (2023–2025)
  • 8.20.4 Business Strategy
  • 8.20.5 SWOT Analysis
  • 8.20.6 Strategic Implications (2026–2032)
  • 8.21 Quantabio
  • 8.21.1 Company Overview
  • 8.21.2 Key Products & Segments
  • 8.21.3 Financial Performance (2023–2025)
  • 8.21.4 Business Strategy
  • 8.21.5 SWOT Analysis
  • 8.21.6 Strategic Implications (2026–2032)
  • 8.22 Paragon Genomics
  • 8.22.1 Company Overview
  • 8.22.2 Key Products & Segments
  • 8.22.3 Financial Performance (2023–2025)
  • 8.22.4 Business Strategy
  • 8.22.5 SWOT Analysis
  • 8.22.6 Strategic Implications (2026–2032)
  • 8.23 Grifols
  • 8.23.1 Company Overview
  • 8.23.2 Key Products & Segments
  • 8.23.3 Financial Performance (2023–2025)
  • 8.23.4 Business Strategy
  • 8.23.5 SWOT Analysis
  • 8.23.6 Strategic Implications (2026–2032)
  • 8.24 BGI
  • 8.24.1 Company Overview
  • 8.24.2 Key Products & Segments
  • 8.24.3 Financial Performance (2023–2025)
  • 8.24.4 Business Strategy
  • 8.24.5 SWOT Analysis
  • 8.24.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

What is the size of the global Genotyping Kits market?
The global Genotyping Kits market is estimated at US$ 1.35 billion in 2025 (base year) and is projected to reach US$ 2.98 billion by 2032.
What is the forecast CAGR for the Genotyping Kits market?
The market is expected to grow at a CAGR of 12.2% from 2026 to 2032, expanding from US$ 1.35 billion in 2025 to US$ 2.98 billion in 2032, roughly 2.2 times its base-year value.
What is Genotyping Kits?
In 2024, the global production of genotyping kits is reach 850,000 units, with an average price of US$1,500 per unit.
How is the Genotyping Kits market segmented by type?
By type, the market is segmented into PCR-Based Kits, Next-Generation Sequencing (NGS) Kits and Microarray-Based Kits.
What are the key applications of Genotyping Kits?
Key applications covered include Medical Diagnostics, Biological Research, Forensic Science, Drug Development and Others.
Which companies are profiled in the Genotyping Kits market report?
Key players profiled include Roche, Thermo Fisher Scientific, Merck, Illumina, Bio-Rad, Promega, Fujirebio and Seegene, among 24 companies covered in total.
What geographies does the Genotyping Kits market analysis include?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
What are the key demand drivers for Genotyping Kits?
The genotyping kit market is experiencing significant growth and technological change, driven by multiple factors.
What are the main risks and barriers in the Genotyping Kits market?
Leading companies are building barriers through "vertical integration + ecological alliances." For example, BGI has connected the multi-omics data platform of 142 tertiary hospitals nationwide, while Berry Genomics has partnered with insurance companies to integrate genetic testing into health insurance products.
Who should buy the Genotyping Kits market report?
The report is intended for manufacturers and solution providers, distributors and end users in Medical Diagnostics, Biological Research and Forensic Science, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Genotyping Kits market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

Select a license
from $3,500.00
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.